Science
The GLP-1 leader expands into psychedelics
Lilly has said it would spend up to $25 billion on acquisitions this year.
Drug Development & Clinical Trials
Get the full scoop on drug development & clinical trials through expert analysis, breaking news updates, and essential context from the Morning Brew team.
Science
First human trial of reverse-aging drug begins
Don’t expect a pill to take you back to 21 any time soon.
Science
New Eli Lilly drug may be the strongest GLP-1 yet
Some of the drug's trial results were about on par with weight loss from gastric bypass surgery.
Science
Novo Nordisk found something Ozempic can’t do
Though it was a long shot, this was one of Novo Nordisk’s last chances to reinvigorate its stock before year's end.
Science
Guy who let himself be bitten by snakes improves antivenom
If commercialized, the product could end up dominating the estimated $600 million market for antivenom.
Science
The MDMA therapy movement is having a rough trip
Three papers were retracted over “protocol violations amounting to unethical conduct.”
Science
Molly might soon be legalized to treat PTSD
New research shows the party drug can help PTSD patients.
Become smarter in just 5 minutes
Morning Brew delivers quick and insightful updates about the business world every day of the week from Wall St. to Silicon Valley.
By subscribing, you accept our Terms & Privacy Policy.
